descriptionPublicationkeyboard_double_arrow_right Article 01 Oct 2020 English Publisher:Elsevier BVJournal:International Journal of Gynecological Cancer, volume 30, page 1,656 (issn: 1048-891X,

Authors: Perrone A. M.; Corrado G.; De Iaco P.;

doi: 10.1136/ijgc-2020-001917

pmid: 32759181

handle: 11585/808497

Cisplatin? Why not?

- Summary
- Subjects
- Metrics

Abstract

We thank our colleagues[1][1] for the questions regarding cisplatin in electrochemotherapy in the skin and mucosal lesions of the vulva and vagina. The choice of drug (bleomycin or cisplatin) has been a topic on which we have reflected for a long time since the first results published in 2013[2][2]

Related Organizations

Policlinico S.Orsola-Malpighi
Italy
Alma Mater Studiorum University of Bologna
Italy

Keywords

Vaginal Neoplasms, Vulvar Neoplasms, Palliative Care; Vulvar and Vaginal Cancer, Electrochemotherapy, Humans, Female, Neoplasms, Second Primary, Cisplatin

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	1
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average